Tri Le headshot
TL

Tri Minh Le

Assistant Professor
Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
Emily Couric Clinical Cancer Center
1335 Lee St
Charlottesville, Virginia 22903
Education
University of Virginia, MD
Residency, University of Virginia
Fellowship, University of Virginia
Biography

Dr. Le received his medical degree from the University of Virginia School of Medicine. He completed his internal medicine residency and fellowship in hematology/oncology at the University of Virginia Health System in Charlottesville, VA. Dr. Le is board certified in internal medicine and medical oncology. He holds a clinical faculty appointment in medicine in the Division of Hematology/Oncology at the University of Virginia. Dr. Le manages patients with gastrointestinal cancers, including cancers of the esophagus, stomach, colon, liver, and pancreas. His research interests are in developmental therapeutics and clinical trial access in gastrointestinal malignancies.

 In his spare time, Dr. Le enjoys spending time outdoors, traveling, and cheering on the UVA Cavaliers.

A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Source: ECOG-ACRIN Cancer Research Group
January 08, 2021 – January 07, 2024
NEOADJUVANT GMCITM PLUS CHEMORADIATION FOR ADVANCED NON-METASTATIC PANCREATIC ADENOCARCINOMA
Source: Advantagene, Inc.
June 15, 2020 – June 14, 2023
MD-INMD-HO - Le - BMS CV202103
Source: Bristol-Myers Squibb Company
May 31, 2019 – May 30, 2022
RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR (ATOMIC)
Source: Alliance for Clinical Trials in Oncology Foundatio
September 12, 2017 – September 11, 2021
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas (Protocol A021501)
Source: Alliance for Clinical Trials in Oncology Foundatio
July 01, 2017 – September 20, 2020
Phase II Study of Regorafenib in Combination with FOLFIRI
Source: University of North Carolina-Chapel Hill
August 29, 2011 – May 09, 2018